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Summary
Background LY3022855 is a recombinant, immunoglobulin, human monoclonal antibody targeting the colony-stimulating factor-1
receptor. This phase 1 trial determined the safety, pharmacokinetics, and antitumor activity of LY3022855 in combination with
durvalumab or tremelimumab in patients with advanced solid cancers who had received standard anti-cancer treatments.Methods In
Part A (dose-escalation), patients received intravenous (IV) LY3022855 25/50/75/100 mg once weekly (QW) combined with
durvalumab 750 mg once every two weeks (Q2W) IV or LY3022855 50 or 100 mg QW IV with tremelimumab 75/225/750 mg
once every four weeks. In Part B (dose-expansion), patients with non-small cell lung cancer (NSCLC) or ovarian cancer (OC) received
recommended phase 2 dose (RP2D) of LY3022855 from Part A and durvalumab 750 mg Q2W. Results Seventy-two patients were
enrolled (median age 61 years): Part A = 33, Part B = 39. In Part A,maximum tolerated dosewas not reached, and LY3022855 100mg
QWand durvalumab 750mgQ2Wwas theRP2D. Four dose-limiting equivalent toxicities occurred in two patients fromOCcohort. In
Part A, maximum concentration, area under the concentration-time curve, and serum concentration showed dose-dependent increase
over two cycles of therapy. Overall rates of complete response, partial response, and disease control were 1.4%, 2.8%, and 33.3%.
Treatment-emergent anti-drug antibodies were observed in 21.2% of patients.Conclusions LY3022855 combined with durvalumab or
tremelimumab in patients with advanced NSCLC or OC had limited clinical activity, was well tolerated. The RP2D was LY3022855
100 mg QW with durvalumab 750 mg Q2W. ClinicalTrials.gov ID: NCT02718911 (Registration Date: May 3, 2011).
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Cancer cells can enhance tumor growth by activating immu-
nosuppressive mechanisms within the tumor microenviron-
ment (TME), which limits T cell function [1, 2]. Inhibitors
of programmed cell death-1 protein (PD-1)/programmed cell
death ligand 1 (PD-L1) and cytotoxic T lymphocyte associat-
ed protein 4 (CTLA-4) have resulted in improving survival in
patients with multiple tumor types, resulting in approvals by
the United States Food and Drug Administration [3, 4].
However, many cancers, such as ovarian cancer (OC), fail to
respond frequently to immune checkpoint blockade, while a
significant proportion of patients with non-small cell lung
cancer (NSCLC) fail to respond or develop resistance to treat-
ment [5].
Tumor-associated macrophages (TAMs), regulated by
binding of colony-stimulating factor-1 (CSF-1)/macrophage
colony-stimulating factor, contribute to tumor growth by dif-
ferent mechanisms, including the support for accumulation of
regulatory T-cells. The accumulation of these regulatory T-
cells suppresses the cytotoxic natural killer and CD8+ T-cells,
in turn increasing angiogenesis and tumor metastasis [6]. It
has been reported that high infiltration of TAMs is an indicator
of worse prognosis in different solid tumors [7]; therefore,
disruption of the immunosuppressive effects of innate im-
mune cells expressing CSF-1 via the CSF-1 receptor (CSF-
1R) may be a promising treatment strategy, as observed in
multiple preclinical studies determining the effect of CSF-
1R blockade via CSF-1 in solid tumors [8–11]. In addition
to CSF-1, interleukin (IL)-34 is a ligand for CSF-1R which
has a different structure but has similar functions as that of
CSF-1 [12].
LY3022855 is a novel, recombinant, immunoglobulin G
sub-class1, human monoclonal antibody (mAb) which pre-
vents binding of CSF-1 and IL-34 to CSF-1R, and inhibits
CSF-1R activation for tumor regulation and growth [13,
14]. Preclinical studies suggested that CSF-1R blockade
with LY3022855 modulates the TME in mouse cancer
models [15]. A previous phase 1 study of LY3022855
monotherapy in patients with metastatic breast cancer
(MBC) demonstrated good tolerability and target engage-
ment activity, with two patients achieving stable disease
(SD) for over nine months [14]. Blockade of PD-1/PD-L1
and CTLA-4 has shown anti-tumor activity in solid tumors
[16], which includes promising anti-tumor activity of PD-
1/PD-L1 in a subset of patients with NSCLC [17, 18], and
limited anti-tumor activity of PD-1/PD-L1 alone or in com-
bination with other checkpoint inhibitors in OC in preclin-
ical setting [19]. To further investigate the dual blockade
strategies of CSF-1R/PD-L1 or CSF-1R/CTLA-4, a phase
1a/1b trial of LY3022855 was conducted, where its safety
and activity in combination with durvalumab (MEDI4736,
anti-PD-L1 mAb) or tremelimumab (anti-CTLA-4 mAb)
were determined in patients with advanced solid cancers
in Part A and advanced NSCLC or OC in Part B.
Patients and methods
Study design
This trial was a multicenter, open-label, phase 1a/1b study of
LY3022855 in combinat ion with durvalumab or
tremelimumab in patients with advanced solid tumors not
amenable to curative therapy (Clinicaltrials.gov ID:
NCT02718911). The study was conducted in two parts to
c h a r a c t e r i z e t h e s a f e t y p r o f i l e , t o l e r a b i l i t y ,
pharmacodynamics, pharmacokinetics (PK), antitumor
activity, and immunogenicity of LY3022855 and
durvalumab or tremelimumab combination. Part A of the
study was a dose-finding/dose-escalation phase to determine
the optimal dose for LY3022855 in combination with
durvalumab or tremelimumab. Part B was a dose-expansion
phase of LY3022855 combined with durvalumab. The sche-
ma for the study design is presented in Fig. 1.
The study was performed in accordance with the
International Conference on Harmonization guidelines and
Declaration of Helsinki. The Institutional Review Board of
each study site approved the study protocol, information bro-
chure, and the informed consent form before study initiation.
Patient population
Adult patients with histologically or cytologically confirmed
solid tumors, measurable and/or non-measurable disease, as
defined by the Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1, Eastern Cooperative Oncology Group perfor-
mance status (ECOG PS) ≤1, who had recovered from the
acute effects of previous treatments for cancer, and had a life
expectancy of ≥12 weeks were included in the study. In Part
A, patients with all solid tumor resistant to curative therapy
were included, whereas in Part B, only patients with NSCLC
or OCwere included. Patients with NSCLCwere refractory to
immune checkpoint inhibitor (ICI) or had relapse after ICI
therapy, and had received at least three lines of therapy.
Patients with OCwho had progressed after no more than three
lines of therapy (with or without platinum) prior to inclusion
were included in Part B.
Patients were excluded from the study if they had previ-
ously undergone surgery, or received LY3022855, mAbs, im-
munosuppressants within 28 days before enrollment; or had
received small molecule therapy, radiation therapy within be-
fore 14 days of enrollment. Patients with presence of a second
primary malignancy, serious preexisting medical conditions,
malignancy or metastasis in the central nervous system, and
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known hypersensitivity to LY3022855, durvalumab, or
tremelimumab were also excluded.
Treatment schedule
In Part A (dose-expansion/escalation), patients were divided
into eight cohorts using a 3 + 3 study design: four cohorts each
of LY3022855 in combination with durvalumab or
tremelimumab.
The LY3022855 and durvalumab cohorts were adminis-
tered intravenous LY3022855 doses of 25, 50, 75, or
100 mg once weekly (QW) in combination with durvalumab
750 mg once every two weeks (Q2W) (cohorts D1A, D2A,
D3A, and D4A). The LY3022855 and tremelimumab combi-
nation was administered as: LY3022855 50 mg QW with
tremelimumab 75 mg once every four weeks (Q4W) (T1A),
LY3022855 100 mg QW with tremelimumab 75 mg Q4W
(T2A), LY3022855 100 mg QW with tremelimumab
225 mg Q4W (T3A), and LY3022855 100 mg QW with
tremelimumab 750 mg Q4W (T4A) (Supplementary
Table S1). After receiving six doses of tremelimumab Q4W,
the frequency of subsequent doses of tremelimumab was re-
duced to once every 12 weeks until discontinuation.
In Part B (disease-specific expansion), patients with
NSCLC (B1) or OC (B2) were treated with LY3022855 and
durvalumab at the maximum tolerated dose (MTD) identified
in Part A.
Objectives and assessments
The primary objective was to characterize the safety profile
and tolerability of the LY3022855 combinations used in this
study. In addition, the study determined a recommended
Phase 2 dose (RP2D) for LY3022855 with durvalumab com-
bination in Part A. Secondary objectives included assessment
of antitumor activity, development of immunogenicity/
treatment-emergent anti-drug antibodies (TE ADAs), and
characterization of PK of LY3022855 with durvalumab. The
combination of LY3022855 with tremelimumab was
deprioritized during the study and therefore, not reported in
this disclosure.
In this study, MTD was defined as the highest tested
dose that had less than 33% probability of causing a dose-
limiting toxicity (DLT). Safety evaluation was performed
using the National Cancer Institute-Common Terminology
Criteria for Adverse Events (NCI-CTCAE) version 4.0
[20], and included adverse events (AEs), their severity,
DLTs with each dose, association between study drug
and AE, and dose adjustments due to AEs. A DLT was
defined as a possible drug-related AE (Grade 3 and
above) occurring during Cycle 1 (the DLT-evaluation pe-
riod), which did not improve to the NCI-CTCAE Grade ≤
2 despite medical management. Grade 2 pneumonitis that
did not resolve to Grade ≤ 1 within three days of best
supportive care were also included as DLTs. Adverse
Fig. 1 Study Design. Dur, durvalumab; MTD, maximum tolerated dose;
NSCLC, non-small cell lung cancer; OC, ovarian cancer; QW, once
weekly; Q2W, once every 2 weeks; Q4W, once every 4 weeks; Tre,
tremelimumab. Note for Part A: Only LY3022855 (in both combinations)
and tremelimumab, but not durvalumab, are dose escalated
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events which met the DLT criteria after Cycle 1 were
defined as dose-limiting equivalent toxicities (DLETs).
Serum sampling for PK analysis is presented in
Supplementary Table S2. The samples were collected at reg-
ular intervals through the first four cycles of treatment. Serum
samples were analyzed for LY3022855 (Covance
Laboratories Inc., Chantilly, Virginia, USA), durvalumab, or
tremelimumab using a validated enzyme-linked immunosor-
bent assay method. Pharmacokinetic parameter estimates for
LY3022855 and durvalumab were determined by standard
noncompartmental methods of analysis using Phoenix
WinNonlin® 8.0 (Certara, L.P.; Princeton, New Jersey,
USA).
Tumor measurements were performed using computed
tomography or magnetic resonance imaging, with antitu-
mor activity assessed in terms of tumor response data
(RECIST version 1.1) [21] and time-to-event variables.
The best overall response (BOR) was defined as response
recorded from the “start of the study treatment until the
end of treatment” [21]. The BOR to treatment included
overall response rate (ORR) and disease control rate
(DCR). Patients were considered to have a tumor response
if they achieve a confirmed complete response (CR) or
partial response (PR).
Immunogenicity data were summarized and assessed, as
appropriate. The measures analyzed included presence of
anti-drug antibodies (ADAs) at baseline, TE ADA, and
ADA titer levels.
Statistical analysis
The estimated sample size for this study was 118 (78
patients in Part A and 40 patients in Part B). In Part A,
sample size was determined primarily by the incidence
of DLTs prior to establishing MTD. Planned enrollment
was approximately 12 to 36 patients in the LY3022855
plus durvalumab combination, and approximately 12 to
42 patients in the LY3022855 plus tremelimumab com-
bination. Every cohort in Part B had planned to enroll
20 patients, which was based on estimation of providing
adequate precision for the estimated incidence rate of
the patients having a specified AE or patients showing
CR or PR to treatment.
The endpoints were described using descriptive anal-
ysis and no hypothesis testing was performed. Data
were presented by cohort and treatment, wherever ap-
propriate. Continuous variables were summarized using
number of patients, percentages, mean (standard devia-
t ion ) , and median (min imum and max imum) .
Categorical endpoints were summarized using number




A total of 72 patients (median age 61 years [range 29–84],
62.5% females) were enrolled in this study: 33 in Part A
(LY3022855 + du rva l umab = 15 ; LY3022855 +
tremelimumab = 18) and 39 in Part B. The majority of the
population (59.7%) was <65 years of age and Caucasian
(97.1%). All patients had received at least one prior therapy
and had history of undergoing surgery, radiotherapy, or sys-
temic therapy. The patients were non-randomly assigned to 10
cohorts among Part A (eight cohorts) and Part B (two cohorts).
All patients were off treatment at the time of analysis and were
followed-up post-discontinuation (Table 1). The dose intensi-
ty in each cohort is presented in Supplementary Table S3.
Safety, toxicity, and recommended phase 2 dose of
LY3022855
No DLT was observed in any of the cohorts; however, four
DLETs were observed in two patients with OC (LY3022855
100 mg QW+ durvalumab 750 mg Q2W cohort), including
one patient with increased blood creatine phosphokinase in
Cycle 4 and one patient with increased amylase, increased
lipase, and autoimmune colitis in Cycle 2. All the reported
DLETs were Grade 3. The DLETs of creatine phosphokinase
elevation and autoimmune colitis were resolved with support-
ive treatment. MTD was not reached. The highest dose of
LY3022855 and durvalumab combination investigated in
Part A (LY3022855 100 mg QW + durvalumab 750 mg
Q2W) was determined to be the RP2D, which was then ad-
ministered in Part B.
Nineteen deaths (26.4%) occurred during the study (Part A:
12; Part B: seven). There were six deaths each in LY3022855
plus durvalumab (40%) and LY3022855 plus tremelimumab
(33.3%) cohorts from Part A, and seven deaths in Part B (four
in NSCLC cohort and three in the OC cohort). Nine deaths
(12.5%) occurred during therapy or within 30 days of discon-
tinuation of therapy: one was due to arterial hemorrhage with-
in 30 days of discontinuation of treatment and eight were due
to progressive disease. Among the 10 deaths that occurred
30 days after the discontinuation of therapy, one was due to
Clostridium difficile infection and nine were due to PD. None
of the deaths were considered related to the study treatment.
Serious adverse events (SAEs) occurred in 26 patients
(36.1%); nine in Part A and 17 in Part B (Table 2). Table 3
presents SAEs in each cohort. No SAE was reported in
LY3022855 25 mg, 50 mg, and 75 mg + durvalumab, and
LY3022855 50 mg + tremelimumab 75 mg cohorts. Serious
AEs of anemia (Grades 2 and 3), pyrexia (Grades 1 and 2),
peritonitis bacterial (Grade 3), respiratory tract infection

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































reported in two patients (2.8%) each in the overall population
(Table 3). Drug-related SAEs were observed in five patients
(6.9%; three in Part A and two in Part B) and included anemia
(one patient), stress cardiomyopathy (one patient), hypothy-
roidism (one patient), autoimmune colitis (one patient), hyper-
sensitivity (one patient), amylase increased and blood creatine
phosphokinase increased (two patients), hyponatremia (one
patient), and rash and rash maculo-papular (two patients).
All treated patients experienced at least one treatment-
emergent adverse event (TEAE) during the study.
Of the total patients, 84.7% had at least one drug-related
TEAEs, with Grade 3 TEAEs being the most common among
all the grades of TEAEs (69.4%, Table 2). Table 4 presents the
most common all-cause TEAEs by grade in each cohort.
Common Grade 3 drug-related TEAEs with ≥5% incidence
rate included anemia (13.9%), increase in blood creatine phos-
phokinase (11.1%), hyponatremia (9.7%), increase in aspar-
tate aminotransferase (8.3%), fatigue (6.9%,), hypertension
(6.9%), increase in lipase (5.6%), and lymphopenia (5.6%).
The frequency of drug-related TEAEs by maximum CTCAE
grade are presented in Supplementary Table S4. Face edema
was a notable drug-related TEAE observed in 26.4% patients.
Common Grade 3 drug-related TEAEs included increase in
blood creatine phosphokinase (11.1%), increase in aspartate
aminotransferase (5.6%), increase in lipase (5.6%), fatigue
(4.2%), maculo-papular rash (4.2%), anemia (2. 8%), increase
in amylase (2.8%), hypertension (2.8%), and pruritus (2.8%).
Pharmacokinetics of LY3022855 and Durvalumab
All patients administered at least one dose of LY3022855 in
combination with either durvalumab or tremelimumab were
included in the PK dataset. LY3022855 exhibited dose-
dependent increases across all metrics of PK exposure over
two cycles of therapy, including maximum concentration,
trough concentration (collected at 168 h), and area under the
concentration-time curve (AUC) (Table 5). Concentrations of
durvalumab were consistent across the PK collection period
from Cycle 1 to Cycle 4 (Cycle 1: 122 [49]; Cycle 2: 131 [59];
Cycle 3 Week 1: 118 [47]; Cycle 3 Week 3: 121 [50]; and
Cycle 4; 147 [57] ([geometric mean, (percentage of coefficient
of variation)])).
Efficacy assessment and best overall response
The median progression-free survival (PFS) was 1.87 months
(95% confidence interval [CI] 1.71, 3.22) in the overall pop-
ulation. Median PFS in cohorts D1A, D2A, and D3A were
4.26 months (95% CI 1.87, 19.17), 1.71 months (95% CI
1.35, 8.51), and 11.93 months (95% CI 1.41, 11.93), respec-
tively. Median PFSwas not reached in cohort D4A, as three of
five patients were censored. For cohorts T1A to T4A, the













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































[NA]), 3.22 months (95% CI, 1.64, 9.01), 1.18 months (95%
CI 0.72, NA), and 2.76 months (95% CI 1.71, 6.18), respec-
tively. Median PFS was 1.68 months (95% CI 1.45, 3.19) and
1.87 months (95% CI 1.58, 6.48) for the NSCLC and OC
cohorts, respectively.
Rates of PR, SD, and DCR were 2.8%, 29.2%, and 33.3%
in the overall population, respectively. One patient in the OC
cohort from Part B (5%) achieved a CR. Patients who
achieved PR were from the LY3022855 + durvalumab cohort
D4A (Fig. 2). The ORR in the overall population was 4.2%
(two patients from cohort D4A and one patient from cohort
B2). All three patients who achieved a response had received
LY3022855 100 mg combined with durvalumab 750 mg.
Figure 2 presents the response to treatment for the overall
population and by parts.
Immunogenicity
Overall TE ADA rate was 21.2% and varied by cohort: 13.3%
for LY3022855 + durvalumab cohorts , 23.5% for
LY3022855 + tremelimumab cohorts, 5.9% for NSCLC co-
hort, and 41.2% for OC cohort. Maximum ADA titers of TE
ADA-positive participants ranged from 1:20 to 1:1280 (medi-
an of 1:60).
Discussion
This is the first study to evaluate dose escalation of
LY3022855 in combinat ion with durvalumab or
tremelimumab in patients with solid cancers. LY3022855
showed acceptable tolerability and safety in both the combi-
nations. The MTD for LY3022855 and durvalumab was not
reached and the dose of LY3022855 100 mg QW and
durvalumab 750 mg Q2W was selected as the RP2D, which
was administered to patients with NSCLC and OC in the
disease-expansion phase. The overall findings from Part A
and Part B suggested limited clinical activity in this heavily
pre-treated population, with reported median PFS at
1.87 months, PR achieved in two (2.8%) patients, and SD
Table 3 Summary of serious adverse events by Cohort
Part A Part A
LY 100 mg LY 100mg + Tre
225
LY 100 mg +
+ Dura LY 100mg + Tre 75 mg mg Tre 750 mg LY + Durb LY + Durb






Abdominal pain (5.3) Stress cardiomyopathy (5.0)
Dysphagia (5.3) Autoimmune colitis (5.0)
Abdominal discomfort
(20.0)
Anemia (20.0) Stomatitis (5.3) Duodenal obstruction (5.0)
Hypothyroidism
(20.0)




Pyrexia (5.3) Intestinal obstruction (5.0)
Delirium (40.0) Respiratory tract infection
(5.3)
Pyrexia (5.0)




Diverticulitis (5.3) Respiratory tract infection
(5.0)
Septic shock (5.3) Upper respiratory tract
infection (5.0)
Dyspnea (5.3) Pulmonary embolism (5.0)
Pneumonia aspiration (5.3)
Pneumothorax (5.3)
All data are presented as (%), unless specified
Dur durvalumab, LY LY3022855, QW once weekly, Q2W once every 2 weeks, SAE serious adverse event, Tre tremelimumab
a Part A: All cohorts were administered durvalumab dose of 750 mg Q2W
bPart B: LY 100 mg QW+ durvalumab 750 mg Q2W
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achieved in 21 (29.2%) patients. In addition to the present
study, other CSF-1R inhibitors have also been investigated
[22]. For solid tumors, CSF-1R inhibitors have been either
evaluated as monotherapy [6, 23, 24] or in combination with
chemotherapy [24, 25] or ICIs [26–28].
In this study, treatment with LY3022855 in combination
with durvalumab or tremelimumab yielded acceptable safety
results. With no DLTs in Part A and four DLETs in Part B,
LY3022855 100 mg QW and durvalumab 750 mg Q2W was
confirmed as the RP2D. Overall, 26 (36%) patients developed
SAEs and five (6.9%) patients had drug-related SAEs; how-
ever, the proportion of drug-related TEAEs was 87.4%. All
the deaths in the study (26.4%) occurred after discontinuation
of treatment and did not have a causal relationship with treat-
ment. Previous phase 1 studies of LY3022855 and other CSF-
1R inhibitors demonstrated a similar safety profile [6, 23–25].
Table 4 Summary of all-cause treatment-emergent adverse events by grade
TEAEs
Common TEAEsa n (%) Grade 3 TEAEsb n (%) Grade 4 TEAEs n (%) Grade 5 TEAE n (%)







27 (37.5) Blood creatine phosphokinase
increased
8 (11.1) Pericardial effusion 1 (1.4)
Decreased appetite 26 (36.1) Hyponatremia 7 (9.7) Sepsis 1 (1.4)
Nausea 25 (34.7) Aspartate aminotransferase
increased
6 (8.3) Platelet count decreased 1 (1.4)
Aspartate aminotransferase
increased
24 (33.3) Fatigue 5 (6.9) Hypertriglyceridemia 1 (1.4)
Abdominal pain 21 (29.2) Hypertension 5 (6.9) Hyponatremia 1 (1.4)
Diarrhea 19 (26.4) Lipase increased 4 (5.6)
Anemia 19 (26.4) Lymphocyte count decreased 4 (5.6)
Face edema 19 (26.4) Abdominal pain 3 (4.2)
Pruritus 19 (26.4) Edema peripheral 3 (4.2)
Edema peripheral 18 (25.0) Blood alkaline phosphatase
increased
3 (4.2)
Pyrexia 17 (23.6) Rash maculo-papular 3 (4.2)
Dyspnea 17 (23.6) Diarrhea 2 (2.8)
Rash maculo-papular 17 (23.6) Peritonitis 2 (2.8)
Cough 6 (22.2) Gamma-glutamyltransferase
increased
2 (2.8)
Periorbital edema 16 (22.2) Neutrophil count decreased 2 (2.8)
Alanine aminotransferase
increased
16 (22.2) Alanine aminotransferase
increased
2 (2.8)
Vomiting 15 (20.8) Amylase increased 2 (2.8)
Hypertension 14 (19.4) Hypercalcemia 2 (2.8)
Myalgia 12 (16.7) Hypokalemia 2 (2.8)
Back pain 11 (15.3) Hyperkalemia 2 (2.8)
Hyponatremia 11 (15.3) Back pain 2 (2.8)
Headache 11 (15.3) Confusional state 2 (2.8)
Constipation 10 (13.9) Pruritus 2 (2.8)
Blood creatinine increased 9 (12.5)




Amylase increased 8 (11.1)
TEAE treatment-emergent adverse event
N = 72, number of patients in the safety population. All data are presented as n (%), unless specified
a. Includes TEAEs reported in 10% or patients
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Combination of CSF-1R inhibitor, pexidartinib, with
durvalumab showed a similar safety profile as other studies
of CSF-1R monotherapy in patients with advanced pancreatic
ductal carcinoma and colorectal cancer. Two DLTs of in-
creased aspartate aminotransferase/increased alanine amino-
transferase were reported [28]. Based on these findings, the
safety and tolerability in our study were consistent with the
observations in Phase 1 studies evaluating CSF-1R inhibitor
monotherapy or its combinations with other therapies. As ob-
served in Phase 1 studies for other CSF-1R inhibitors [6,
23–25], MTD was not reached for LY3022855 + durvalumab
combination and the highest administered dose was confirmed
as the RP2D. The safety profile of LY3022855 in this study
was similar to the safety profile observed in another phase I
trial of LY3022855 in patients with MBC or metastatic
castration-resistant prostate cancer (MCRPC), in which the
most frequent TEAEs of any grade included fatigue
(38.2%), decrease in appetite (26.5%), and nausea (26.5%).
Increases in lipase (23.5%) and creatine phosphokinase
(20.6%) were also reported [14]. Occurrence of face edema
(26.4%) in our study, a class effect of CSF-1R inhibitors, was
consistent as observed with other CSF-1R inhibitors.
However, the occurrence of face edema was lower than that
observed with other CSF-1R mAbs [22].
LY3022855 exhibited a dose-dependent increase in expo-
sure and slow elimination [29]. Exposures of LY3022855 in
combination with durvalumab or tremelimumab are compara-
ble to those observed in monotherapy studies [14, 29].
Similarly, combination with LY3022855 did not appear to
affect durvalumab PK, with exposures which were consistent
with monotherapy PK, as reported by Baverel et al. in patients
with urothelial carcinoma and NSCLC [30]. The linear in-
crease in PK parameters for LY3022855 was in alignment
with other CSF-1R inhibitors [6, 24, 25]. Pharmacokinetics
of AMG820, a CSF-1R inhibitor, was non-linear in the dose
range of 1.5 mg/kg to 6 mg/kg due to small cohort size; how-
ever, AUC and maximum serum concentration increased with
dose in the 1.5 mg/kg to 20 mg/kg dose ranges [6].
Table 5 Noncompartmental PK Analysis of LY3022855 100 mg QW and Durvalumab 750 mg Q2W in Part A
LY3022855 Durvalumab
Cycle 1 2 1
N 44 29 38
Cmax (mg/mL) 32.9 (28) 43.1 (38) 251 (32)
tmaxa (h) 2.06 (0.48–21.82) 1.83 (0.97–27.75) 1.58 (1–24.28)
t1/2b (h) 63.4c (36.4–104) 116d (42.1–316) –
C168h (mg/mL) 5.00e (69) 13.4f (84) –
Cav,τ (mg/mL) 14.9g (33) 27.1h (32) –
AUC(0-∞) (h∙mg/mL) 5250c (49) 7490d (56) –
AUC(0-τ)i (h∙mg/mL) 2500g (33) 4560h (32) 31900j (55)
CL (L/h) 0.0401g (33) 0.0219h (43) –
Vss (L) 9.31c (63) 3.69d (35) –
RAk – 1.93d (32) –
AUC(0-τ) area under the concentration versus time curve from time zero to τ,AUC(0-∞) area under the concentration versus time curve from time zero to∞,
C168h serum concentration collected 168 h after the start of infusion, Cav,τ average serum concentration over dosing interval calculated using AUC(0-τ),
CL total body clearance, Cmax maximum serum concentration, h hours, N number of patients in the analysis population, QW once a week, Q2W once
every 2 week, RA intrapatient accumulation ratio, t1/2 terminal elimination half-life, tmax time of maximum serum concentration, Vss volume of
distribution at steady state
aMedian (minimum, maximum)
bGeometric mean (minimum, maximum)
cN = 30 patients
d = 21 patients
e N = 31 patients
f N = 24 patients
g N = 35 patients
h N = 22 patients
i τ = 168 h for LY3022855; 336 h for durvalumab
j N = 6 patients
k RA =AUC(0-τ) Cycle 1/AUC(0-τ) Cycle 2
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Pexidartinib followed linear PK up to a dose of 1200 mg [25],
whereas emactuzumab followed linear PK above dose of
900 mg [24]. Overall, the PK of LY3022855 was consistent
with typical IgG1 mAb PK [31].
The overall response to treatment and improvement in me-
dian PFS with LY3022855 combination with durvalumab or
tremelimumab were limited. With the RP2D of LY3022855
100 mg QW+ durvalumab 750 mg Q2W, a BOR of SD and
PR was achieved in 40% patients across Parts A and B.
During the interim analysis of this study, one patient (2.8%)
achieved SD from the 35 evaluated patients [29]. Compared
with LY3022855, the rate of SD was 13% with emactuzumab
monotherapy and 43% with emactuzumab and paclitaxel
combination therapy [24]. In the MEDIPLEX study, 21% of
patients achieved SD after pexidartinib and durvalumab com-
bination [28]. LY3022855 also showed limited clinical activ-
ity in patients with MBC or MCRPC, with no patient achiev-
ing CR or PR. The rate of SD was 22.7% in patients with
MBC and 42.8% in patients with MCRPC [14]. Because
TME modulation may be a critical factor for efficacy, the
combination of a CSF-1R inhibitor with other immunotherapy
agents was hypothesized to be a promising strategy. The lim-
ited clinical benefit observed from our study and other studies
may be attributed to unexplored or unknown resistance mech-
anisms [22]. In addition, the limited clinical response of ICIs
(inhibitors of CSF-1R, PD-L1, and CTLA-4) in patients with
advanced solid cancers, including NSCLC and OC, suggested
that the population in the presented study was difficult to treat
and hence had limited clinical activity [17–19, 22].
The overall low TE ADA rate of 21.2% for LY3022855,
with low ADA titers, suggests low risk for any potential im-
pact on exposure or efficacy. More importantly, no safety
events related to ADA were detected. The overall low ADA
titers in TE ADA-positive participants suggest low risk for
ADA impact on exposure or efficacy. The proportion of TE
ADA-positive patients in our study was higher than the pro-
port ion of healthy subjects developing ADAs to
lacnotozumab in a phase 1 study (7.7%) [32]. Because no data
have been reported on the ADAs for other CSF-1Rs [6,
23–25, 28], comparison with other CSF-1Rs with respect to
ADA development could not be done.
This study has several limitations. First, the limited efficacy
could have been due to the difficult-to-treat patient population
enrolled in this study. Second, determining the duration of SD
was not part of the planned analysis. Third, exploratory anal-
ysis on the pharmacodynamic effects of LY3022855 and
durvalumab or tremelimumab combinations was not per-
formed due to low sample size and lack of data. Despite these
limitations, investigation of the safety of these combinations
may be important for future research.
Supplementary Information The online version contains supplementary
material available at https://doi.org/10.1007/s10637-021-01088-4.
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